Table 4 Baseline levels and slope changes* of the biomarkers during enzyme-replacement therapy: impact of covariates
From: Bone events and evolution of biologic markers in Gaucher disease before and during treatment
Biomarker | Covariate(s) | N | Baseline | P | CVa | Slope of % decreaseb | P | CVa |
|---|---|---|---|---|---|---|---|---|
Platelets | ||||||||
No splenectomy | 38 | 108,850 (/mm3) | 56.5% | 7 035 (/mm3/yr) | 80.7% | |||
Splenectomy | 20 | 309,380 (/mm3) | -882 (/mm3/yr) | |||||
Effect of splenectomy | <0.0001 | 0.0007 | ||||||
Chitotriosidase | ND | |||||||
No splenectomy-N370S | 6 | 14,721 nmol/mL/h | 9.8% | -38% (/yr) | ||||
No splenectomy-other genotype | 22 | 3,581 nmol/mL/h | -14% (/yr) | |||||
Splenectomy-N370S | 2 | 8,283 nmol/mL/h | -27% (/yr) | |||||
Splenectomy-other genotype | 11 | 2,015 nmol/mL/h | -2% (/yr) | |||||
Effect of splenectomy | 0.19 | 0.015 | ||||||
Effect of genotype | 0.006 | 0.018 | ||||||
Ferritin | 47 | 382 ng/L | 15.4% | -14% (/yr) | 83.6% | |||
ACE | ||||||||
Diagnosis before 1991 | 35 | 90.3 (IU/L) | 25.5% | -7% (/yr) | 190.1% | |||
Diagnosis in 1991 and after | 11 | 31.7 (IU/L) | 4% (/yr) | |||||
Effect of diagnosis data | 0.020 | 0.055 | ||||||
TRAP | ||||||||
No splenectomy-diagnosis >15 yr | 10 | 4.2 (IU/L) | 3.6% | -4% (/yr) | ND | |||
No splenectomy-diagnosis 15 yr | 13 | 6.6 (IU/L) | -9% (/yr) | |||||
Splenectomy-diagnosis >15 yr | 5 | 3.5 (IU/L) | 3% (/yr) | |||||
Splenectomy-diagnosis <15 yr | 8 | 5.4 (IU/L) | -2% (/yr) | |||||
Effect of splenectomy | 0.32 | 0.004 | ||||||
Effect of age at diagnosis | 0.016 | 0.057 |